ViaDerma(OTC) VDRM

ViaDerma, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceutical products. The company also licenses its proprietary technology to other firms in the pharmaceutical sector, addressing various therapeutic areas.

Products and Services

• Vitastem, a topical antibiotic effective for treating various skin ailments
• Advanced topical antibiotics and antifungal treatments in development
• Expanding pipeline for medical cannabis applications and anti-aging formulations

Growth Outlook

• Recent revenue of $150,189 in Q3 2024 shows consistent sales performance
• Ongoing development in diverse therapeutic areas enhances market potential
• Strong gross profit margin of approximately 99.97% indicates effective cost management

Financial Highlights

• Net income of -$321,554 in Q3 2024 reflects ongoing investment in growth
• Cash and cash equivalents increased to $1,491,343 in Q3 2024
• Current ratio of 1.10 suggests adequate short-term financial health

ViaDerma, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry, and is headquartered in Marina Del Rey, California. The company has a diverse product pipeline that includes not only its flagship product, Vitastem, but also a range of potential treatments for conditions such as acne, psoriasis, and skin cancer. The focus on innovative solutions positions ViaDerma to capitalize on growing market demands in the pharmaceutical sector. Recent financial data indicates a commitment to growth, despite challenges reflected in net income figures. The company’s strong gross profit margin suggests effective management of production costs, while the increase in cash reserves provides a buffer for future investments. Overall, ViaDerma, Inc. presents a compelling opportunity for investors interested in the pharmaceutical industry.